The identification of AEG‐1 as a key regulator of hypoxia‐induced chemoresistance in HCC highlights its potential as a therapeutic target, emphasizing the need to disrupt the PI3K/AKT/HIF‐1α/MDR‐1 pathway to enhance chemotherapy efficacy. The gene discussed is PIK3CB; the disease is hepatocellular carcinoma.